On the 22nd of January, the Hyderabad based Bharat Biotech International Private Limited announced to administer 2nd dose of COVAXIN to 13,000 volunteers.
The second dose of the Novel Coronavirus or COVID-19 vaccine COVAXIN was given under the phase-3 trials.
Suchitra Ella, the Joint Managing Director of Bharat Biotech International Limited, thanked the volunteers for their pro-vaccine public health volunteerism. The announcement came amid the continuing administration of COVAXIN from the 16th of January under the nationwide COVID-19 vaccination drive.
The Hyderabad-based firm had on the 7th of January announced that it completed the recruitment of 25,800 people for its phase 3 trials.
On the 2nd of January, the company said that it has recruited 23,000 volunteers.
The next day Drugs Controller General of India (DCGI) approved its restricted use in the clinical trial mode.
The phase-3 human clinical trials of COVAXIN began mid November 2020 with a target to vaccinate 26,000 volunteers across India.
This is India’s first and only phase-3 efficacy study for COVID-19 vaccine and the largest phase-3 efficacy trial ever conducted for any vaccine in India.
COVAXIN is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses.
India’s first indigenous Covid-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) — National Institute of Virology (NIV).
This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Biosafety Level 3) bio-containment facility, one of its kind in the world.
Bharat Biotech started supply of the second consignment containing over 25 lakh doses of Covaxin to 22 cities across India.
COVAXIN along with Serum Institute of India’s Covishied vaccine are part of the Government’s mass vaccination programme.
Earlier on the 13th of January, the first tranche of 2.4 lakh Covaxin doses were flown to 11 cities.
Stay tuned for further updates.
